A multicenter phase II study of docetaxel 60 mg/m 2 as first-line chemotherapy in patients with advanced or recurrent breast cancer

Breast Cancer

Volumn 11, Issue 4, 2004, Pages 374-379

  Ishikawa, Takashi ^a   Shimizu, Satoru ^b   Inaba, Masaaki ^c   Asaga, Taro ^c   Katayama, Kiyohumi ^b   Fukuda, Mamoru ^d   Tokuda, Yutaka ^e   Ishida, Kazuo ^f   Fukuma, Eisuke ^g   Suda, Takashi ^b   Hamaguchi, Yohei ^b   Ishiyama, Akira ^b   Shimada, Hiroshi ^h  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOKAI UNIVERSITY   (Japan)

^f KITASATO UNIVERSITY   (Japan)

^g KAMEDA MEDICAL CENTER   (Japan)

^h YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Advanced breast cancer; Docetaxel; First line chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; TAXOID;

ADULT; AGED; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; HUMAN; JAPAN; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PALLIATIVE THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; JAPAN; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 21644460994     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02968045     Document Type: Article

References (18)

1. Aapro MS: Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings. Semin Oncol 26:17-21, 1999. (Pubitemid 29153676)
2. A'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type schedules. Br J Cancer 67:801-805, 1993. (Pubitemid 23101563)
3. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930-942, 1998.
4. Crown J: A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer. Semin Oncol 26:5-9, 1999. (Pubitemid 29153674)
5. Ravdin PM, Burris HA I I I, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE: Phase II trial of docetaxel in advanced anthracyclineresistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995.
6. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995.
7. Sjostrom J, Mourisden H, Pluzanska A, Ottosson L, Bengtsson N-O, Ostenstad B: Taxotere (T) versus methotrexate-5-fluorouracil (MF) in patients with advanced anthracycline-resistant breast cancer: preliminary results of a randomized phase III study by Scandinavian Breast Cancer Group. Proc Am Soc Clin Oncol 17:111a (abtstr. 427), 1998.
8. Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Fargeot P, Assadourian S: Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 18:1210-1215, 2002. (Pubitemid 36009124)
9. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, T. A. Vandenberg, B. Rapoport, R. Rosso, V. Trillet-Lenoir, J. Drbal, A. Molino, J. W. R. Nortier, D. J. Richel, T. Nagykalnai, P. Siedlecki, N. Wilking, J. Y. Genot, P. S. G. J. Hupperets, F. Pannuti, D. Skarlos, E. M. Tomiak, M. Murawsky, M. Alakl, A. Riva, M. Aapro, 304 Study Group. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17:1413-1424, 1999. (Pubitemid 29220847)
10. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 8:2341-2354, 1999. (Pubitemid 29368232)
11. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322, 1995.
12. Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Maugard-Louboutin C, Dieras V, Azli N, Bougon N, Riva A, Roche H: A multicentre phase II study of the efficacy and safety of docetaxel as firstline treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 7:165-171, 1996. (Pubitemid 26094881)
13. Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14:58-65, 1996.
14. Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, Vandenberg TA, Delorme F, Muldal AM: Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:422-428, 1996.
15. 2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. Br J Cancer 74:650-656, 1996. (Pubitemid 26279065)
16. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M: Paclitaxel versus doxorubicin as first-line singleagent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 4:724-733, 2000. (Pubitemid 30106602)
17. Adachi I, Watanabe T, Takashima S, Narabayashi M, Horikoshi N, Aoyama H, Taguchi T: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 73:210-216, 1996. (Pubitemid 26028336)
18. 2 in patients with metastatic breast cancer according to the status of anthracycline resistance. J Clin Oncol 19:336-342, 2001. (Pubitemid 32112844)